{"id":5571,"date":"2026-01-20T05:48:44","date_gmt":"2026-01-20T05:48:44","guid":{"rendered":"https:\/\/mediumslateblue-snake-278037.hostingersite.com\/?p=5571"},"modified":"2026-01-20T05:48:45","modified_gmt":"2026-01-20T05:48:45","slug":"pharmac-to-fully-fund-rare-disorder-drug-nitisinone-from-2026","status":"publish","type":"post","link":"https:\/\/cvnznews.com\/?p=5571","title":{"rendered":"Pharmac to Fully Fund Rare Disorder Drug Nitisinone From 2026"},"content":{"rendered":"\n<p>Pharmac will begin funding the drug nitisinone for New Zealanders living with the rare metabolic disorders tyrosinemia type 1 and alkaptonuria from <strong>1 February 2026<\/strong>, shifting the treatment from its current case\u2011by\u2011case approval pathway to full listing on the Pharmaceutical Schedule.<\/p>\n\n\n\n<p>The move is expected to benefit around <strong>10 people nationwide in the first year<\/strong> of funding.<\/p>\n\n\n\n<p>Pharmac\u2019s Acting Manager of Pharmaceutical Funding, <strong>Claire Pouwels<\/strong>, said the decision would significantly streamline access for patients and clinicians.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThis decision will make it easier for people living with these rare conditions to access nitisinone,\u201d Pouwels said. \u201cIt will also make it easier for clinicians to prescribe this treatment, without needing to apply through NPPA each time.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>Nitisinone is currently accessed through Pharmac\u2019s <strong>Named Patient Pharmaceutical Assessment (NPPA)<\/strong> process, which requires individual clinical applications. From 2026, the medicine will be routinely available, removing administrative barriers and providing greater certainty for families and clinicians.<\/p>\n\n\n\n<p>Clinicians have backed the decision, saying the change will simplify treatment pathways for patients with these lifelong conditions.<\/p>\n\n\n\n<p>Rare Disorders New Zealand also previously supported the proposal, noting that a scheduled listing would reduce administrative burden and improve transparency around access criteria.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>About the Conditions<\/strong><\/h2>\n\n\n\n<p>Tyrosinemia type 1 and alkaptonuria are inherited metabolic disorders that affect the body\u2019s ability to break down the amino acid tyrosine. Without treatment, toxic by\u2011products can accumulate, leading to serious health complications.<br>Nitisinone, used alongside a controlled diet, can prevent or reduce these harmful effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Brand Change and Support Pathways<\/strong><\/h2>\n\n\n\n<p>People already receiving nitisinone through NPPA will continue treatment uninterrupted, but may need to transition to the <strong>LogixX Pharma<\/strong> brand from February 2026.<\/p>\n\n\n\n<p>Pharmac says that if patients experience issues with the new brand, clinicians can apply for an alternative under the <strong>Exceptional Circumstances<\/strong> framework.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Government Response<\/strong><\/h2>\n\n\n\n<p>Searches show <strong>no public statements from health ministers or Te Whatu Ora officials<\/strong> regarding this funding decision. The announcement appears to have been made solely by Pharmac, with commentary from clinicians and Rare Disorders NZ supporting the move.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>Pharmac will begin funding the drug nitisinone for New Zealanders living with the rare metabolic disorders tyrosinemia type 1 and alkaptonuria from 1 February 2026, shifting the treatment from its current case\u2011by\u2011case approval pathway to full listing on the Pharmaceutical Schedule. The move is expected to benefit around 10 people nationwide in the first year<\/p>\n","protected":false},"author":1,"featured_media":5528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"coauthors":[],"class_list":{"0":"post-5571","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-new-zealand"},"_links":{"self":[{"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/posts\/5571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5571"}],"version-history":[{"count":1,"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/posts\/5571\/revisions"}],"predecessor-version":[{"id":5576,"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/posts\/5571\/revisions\/5576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=\/wp\/v2\/media\/5528"}],"wp:attachment":[{"href":"https:\/\/cvnznews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5571"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cvnznews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcoauthors&post=5571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}